Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 33,013 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo controlled Clear all

Conditions: Cocaine Use Disorder, Anxiety
Interventions: suvorexant, Placebo (for suvorexant); Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 19 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Complicated Intra-abdominal Infections, Complicated Appendicitis
Interventions: Eravacycline, Meropenem, Placebo; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Indianapolis, Indiana • Las Vegas, Nevada + 3 more

Conditions: Healthy, Frontotemporal Dementia
Interventions: AL001, Placebo; Biological · Other
Lead sponsor: Alector Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), Sham; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibromyalgia
Interventions: Placebo, Milnacipran 100mg; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,025 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 24
States / cities: Tuscaloosa, Alabama • Fresno, California • Pismo Beach, California + 20 more

Conditions: Healthy
Interventions: meropenem-vaborbactam, Placebo, Moxifloxacin; Drug
Lead sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Covid-19
Interventions: Octagam 10%, Saline Solution; Biological · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Sheffield, Alabama • Loma Linda, California • Newport Beach, California + 11 more

Conditions: Healthy Volunteers
Interventions: Drug: ABBV-1088, Drug: Placebo for ABBV-1088; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: anamorelin HCl, placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more

Conditions: Parkinson Disease, Depression
Interventions: Psilocybin, Pimavanserin; Drug
Lead sponsor: Joshua Woolley, MD, PhD; Other
Eligibility: 40 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Vulvovaginal Candidiasis
Interventions: Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 611 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Nicotine Dependence
Interventions: Placebo, Varenicline; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neurological Disorder
Interventions: Glyceryl Tribenzoate; Drug
Lead sponsor: Forest Hills Lab; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bloomfield, New Jersey

Conditions: Juvenile Neuronal Ceroid Lipofuscinosis
Interventions: Mycophenolate mofetil, Liquid Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 6 Years to 25 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Asthma
Interventions: Montelukast, Sugar pill; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson Disease
Interventions: sumanirole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 60 more

Conditions: Healthy
Interventions: Citicoline, Placebo; Dietary Supplement
Lead sponsor: Kirin Holdings Company, Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alzheimer's Disease
Interventions: ABT-957, Placebo for ABT-957; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Glendale, California • Orlando, Florida • New York, New York + 1 more

Conditions: Long QT Syndrome Type 3
Interventions: Eleclazine, Eleclazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Rochester, New York

Conditions: Depressive Disorder
Interventions: orvepitant, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 27
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 23 more

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Orelabrutinib, Placebo; Drug
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 27
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 23 more

Conditions: Post Traumatic Stress Disorder
Interventions: Modius Spero active device, Sham device; Device
Lead sponsor: Neurovalens Ltd.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Transcranial Magnetic Stimulation (TMS) and Obsessive Compulsive Disorder (OCD)

Study of Milnacipran for the Treatment of Fibromyalgia

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Psilocybin Therapy for Depression in Parkinson's Disease

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

Effects of Chantix on Relapse Prevention for Smoking Cessation

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Moderate to Persistent Asthma in the Obese Subject

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

Evaluate the Effects of Citicoline on Mood in Healthy Adults

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for PTSD